UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Extramammary Paget's Disease

Hematology/oncology clinics of North America, 2019-02, Vol.33 (1), p.73-85

2019

Volltextzugriff (PDF)

Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid

JAMA dermatology (Chicago, Ill.), 2017-06, Vol.153 (6), p.603

2017

Volltextzugriff (PDF)

Cutaneous adverse events caused by immune checkpoint inhibitors

Journal of the American Academy of Dermatology, 2021-10, Vol.85 (4), p.956-966

2021

Volltextzugriff (PDF)

Bullous pemphigoid after anti–programmed death-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes

Journal of the American Academy of Dermatology, 2022-12, Vol.87 (6), p.1400-1402

2022

Volltextzugriff (PDF)

Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax

Cancer discovery, 2017-02, Vol.7 (2), p.156-164

2017

Volltextzugriff (PDF)

Geographic disparities in access to scalp cooling for the prevention of chemotherapy-induced alopecia in the United States

Journal of the American Academy of Dermatology, 2021-11, Vol.85 (5), p.1248-1252

2021

Volltextzugriff (PDF)

Dermatological adverse events with taxane chemotherapy

EJD. European journal of dermatology, 2016-10, Vol.26 (5), p.427-443

2016

Volltextzugriff (PDF)

Mogamulizumab Forecast: Clearer Patients, with a Slight Chance of Immune Mayhem

Clinical cancer research, 2019-12, Vol.25 (24), p.7272-7274

2019

Volltextzugriff (PDF)

Ipilimumab for Patients with Relapse after Allogeneic Transplantation

The New England journal of medicine, 2016-07, Vol.375 (2), p.143-153

2016

Volltextzugriff (PDF)

Treatment of immune checkpoint inhibitor–mediated psoriasis: A systematic review

Journal of the American Academy of Dermatology, 2022-08, Vol.87 (2), p.399-400

2022

Volltextzugriff (PDF)

Evaluation of a Comprehensive Skin Toxicity Program for Patients Treated With Epidermal Growth Factor Receptor Inhibitors at a Cancer Treatment Center

JAMA dermatology (Chicago, Ill.), 2020-10, Vol.156 (10), p.1079

2020

Volltextzugriff (PDF)

Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy

JAMA dermatology (Chicago, Ill.), 2022-02, Vol.158 (2), p.189

2022

Volltextzugriff (PDF)

Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor–induced dermatologic adverse events

Journal of the American Academy of Dermatology, 2023-06, Vol.88 (6), p.1271-1281

2023

Volltextzugriff (PDF)

Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI)

British journal of cancer, 2020-11, Vol.123 (10), p.1535-1542

2020

Volltextzugriff (PDF)

Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy

Journal of clinical oncology, 2016-04, Vol.34 (10), p.e87-e89

2016

Volltextzugriff (PDF)

Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors

JAMA dermatology (Chicago, Ill.), 2022-05, Vol.158 (5), p.552

2022

Volltextzugriff (PDF)

Outcomes of Acitretin Treatment for Refractory Multikinase Inhibitor-Induced Hand-Foot Skin Reaction

JAMA dermatology (Chicago, Ill.), 2022-07, Vol.158 (7), p.824

2022

Volltextzugriff (PDF)

S225 Infliximab Versus Vedolizumab in Outpatient Treatment of Immune Checkpoint Inhibitor Colitis

The American journal of gastroenterology, 2024-10, Vol.119 (10S), p.S164-S165

2024

Volltextzugriff (PDF)

An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions

American journal of clinical dermatology, 2020-12, Vol.21 (6), p.821-832

2020

Volltextzugriff (PDF)

Characterization of adverse cutaneous effects in the setting of enfortumab vedotin for metastatic urothelial carcinoma: A retrospective review

Journal of the American Academy of Dermatology, 2024-10, Vol.91 (4), p.753-755

2024

Volltextzugriff (PDF)

Overview of Cutaneous T-Cell Lymphomas

Hematology/oncology clinics of North America, 2019-08, Vol.33 (4), p.669-686

2019

Volltextzugriff (PDF)

TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL

Science translational medicine, 2015-10, Vol.7 (308), p.308ra158

2015

Volltextzugriff (PDF)

Cutaneous immune‐related adverse events from immune checkpoint inhibitor therapy: Moving beyond “maculopapular rash”

Immunological reviews, 2023-09, Vol.318 (1), p.22-36

2023

Volltextzugriff (PDF)

Impact of biologic therapy on cancer outcomes in patients with immune checkpoint inhibitor–induced bullous pemphigoid

Journal of the American Academy of Dermatology, 2023-03, Vol.88 (3), p.670-671

2023

Volltextzugriff (PDF)

1 – 25 von 223

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(201)
Mit Volltextzugriff
(179)

Publikationsform

Sprache

Englisch
(219)
Französisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(131)
Life Sciences & Biomedicine
(125)
Humans
(89)
Dermatology
(63)
Oncology
(43)
Immunotherapy
(37)
Male
(34)
Female
(32)
Aged
(25)
Cancer
(25)
Middle Aged
(22)
Retrospective Studies
(22)
Immune Checkpoint Inhibitors
(20)
Patients
(19)
Immune Checkpoint Inhibitors - Adverse Effects
(16)
Adult
(15)
Cancer Therapies
(14)
Immune-Related Adverse Events
(14)
Melanoma
(14)
Skin
(14)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Extramammary Paget's Disease

Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid

Cutaneous adverse events caused by immune checkpoint inhibitors

Bullous pemphigoid after anti–programmed death-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes

Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax

Geographic disparities in access to scalp cooling for the prevention of chemotherapy-induced alopecia in the United States

Dermatological adverse events with taxane chemotherapy

Mogamulizumab Forecast: Clearer Patients, with a Slight Chance of Immune Mayhem

Ipilimumab for Patients with Relapse after Allogeneic Transplantation

Treatment of immune checkpoint inhibitor–mediated psoriasis: A systematic review

Evaluation of a Comprehensive Skin Toxicity Program for Patients Treated With Epidermal Growth Factor Receptor Inhibitors at a Cancer Treatment Center

Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy

Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor–induced dermatologic adverse events

Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI)

Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy

Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors

Outcomes of Acitretin Treatment for Refractory Multikinase Inhibitor-Induced Hand-Foot Skin Reaction

S225 Infliximab Versus Vedolizumab in Outpatient Treatment of Immune Checkpoint Inhibitor Colitis

An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors

Characterization of adverse cutaneous effects in the setting of enfortumab vedotin for metastatic urothelial carcinoma: A retrospective review

Overview of Cutaneous T-Cell Lymphomas

TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL

Cutaneous immune‐related adverse events from immune checkpoint inhibitor therapy: Moving beyond “maculopapular rash”

Impact of biologic therapy on cancer outcomes in patients with immune checkpoint inhibitor–induced bullous pemphigoid

Suchergebnisse filtern